Articles tagged with Target Mrna
Researchers at UMass Amherst have developed a unique tool for studying RNA, allowing them to observe its behavior inside live cells. The three-color method uses glowing proteins that target specific parts of the RNA molecule, providing valuable insights into RNA's functions and how they impact cellular health.
Researchers found that abundant mRNA molecules tend to cluster together in brain neurons, driven by chance overlap rather than coordinated movement. This discovery provides insights into how neurons manage genetic instructions and supports learning and memory, with potential implications for conditions like Fragile X syndrome.
Researchers have developed a new mRNA vaccine technology using albumin-recruiting lipid nanoparticles to deliver vaccines precisely to lymph nodes, avoiding liver toxicity. The approach outperformed traditional delivery systems in laboratory tests, producing strong antitumor T-cell responses and high levels of neutralizing antibodies.
Researchers at Nagoya University have developed a new lipid nanoparticle that delivers mRNA five times more efficiently, allowing better delivery of genetic instructions to cells. The study showed significant improvements in mRNA delivery and effective suppression of tumor growth in mice.
Researchers at Lund University are advancing knowledge about lipid nanoparticles, which could guide them to the right destination within cells. The technique has potential for treating cancer, genetic disorders, and neurological conditions.
A team from Kyushu University has discovered that the smallest known protein-based tRNA-processing enzyme, HARP, forms a star-shaped complex to cut both ends of tRNA. This finding sheds light on how HARP processes the 5' leader sequence and reveals a new mechanism for RNA processing.
Researchers have developed a cheap and sustainable way to produce ionisable lipids from cashew nutshell liquid, a by-product of the cashew industry. This breakthrough could transform the future of vaccine production and support Africa's target of producing 60% of its vaccines locally by 2040.
The BNT162b2 vaccine not only targets the COVID-19 virus but also helps reduce and control innate inflammation to other bacterial and fungal pathogens. By reprogramming innate immune cells, the vaccine reduces pro-inflammatory mediators, providing potential benefits beyond its primary target.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
A new study reports on five patients with Canavan disease who have a novel variant identified through targeted long-read sequencing, revealing an SVA_E retrotransposable element that disrupts gene function. The findings enhance genetic diagnostics and enable improved guidance for families.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
Researchers have discovered genetic properties in prostate cancer that can be targeted to improve patient outcomes, particularly for Chinese men. The findings highlight the potential of precision medicine and more effective treatments.
Research highlights the oncogenic potential of microRNAs in lung cancer, their dysregulation, and functional roles. Dysregulated miRNAs can contribute to tumor progression, metastasis, and chemotherapy resistance.
Researchers have discovered RNA pseudouridine as a novel diagnostic target for colorectal cancer. The study found correlations between pseudouridine modifications and clinical markers, enabling potential non-invasive diagnosis. The findings provide a molecular framework for RNA epigenetics-based stratification and targeted interventions.
Researchers at Tokyo University of Science have made breakthroughs in delivering gene-targeting compounds to the brain, using cholesterol-modified oligonucleotides that can penetrate the cerebral cortex beyond the blood vessels. This could lead to new treatments for diseases such as Alzheimer's and Parkinson's, as well as brain cancers.
STITCHR uses an RNA system to replace entire genes, overcoming CRISPR limitations in targeting every mutation. The tool offers a one-and-done approach for gene therapy, addressing cystic fibrosis and other diseases with thousands of mutations.
This study reveals NAT10 is crucial for spermatogonial proliferation and differentiation. In Nat10-deficient mice, infertility occurs with reduced testicular sizes, germ cell depletion, and a loss of spermatogonial homeostasis.
Researchers have discovered a key cellular mechanism regulating mRNA vaccine delivery and stability, proposing a new paradigm for mRNA therapeutics. The study highlights the importance of N1-methylpseudouridine modification in enhancing mRNA vaccine effectiveness.
The study highlights ICRAFT's ability to pinpoint genes like TNFAIP3 (A20) with dual immunoregulatory effects in both tumor cells and immune cells.
Researchers from Prof. Yardena Samuels's lab developed a new approach to cancer treatment by manipulating cancer cells to produce dozens of suspicious proteins, leading to a powerful immune response that destroys human cancer cells and slows tumor growth in mouse models.
A new study by researchers at McGill University found that annual COVID-19 vaccine booster doses help avoid breakthrough infections in people with immune-mediated inflammatory diseases. The study tracked 366 patients across Canada and used saliva PCR tests and antibody measurements, offering a more precise picture of infection risks.
A new class of zwitterionic phospholipids, DOPE-Cx, enhances the functional delivery of mRNA via lipid nanoparticles, overcoming endosomal escape and improving mRNA expression. This breakthrough paves the way for advanced therapeutic applications, including mRNA vaccines, cancer treatment, and protein replacement therapy.
Researchers mapped m6A patterns across 162 prostate cancer tumors and found that these modifications were closely tied to tumor aggressiveness. Analyzing m6A tags could help doctors predict disease behavior and determine personalized treatment strategies for patients with prostate cancer.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
Researchers developed a synthetic mRNA that revitalizes the immune system to recognize and attack metastasizing cancer cells, significantly reducing metastasis in mice and human cells. The treatment shows promise for use in patients with colon and breast cancers, outperforming existing therapies.
Researchers used CRISPR to cut a single gene from cancer cells of head and neck tumors, resulting in the elimination of 50% of the tumors after 84 days. This groundbreaking study demonstrates that some genes are essential for cancer cell survival, making them excellent targets for CRISPR therapy.
Researchers found that PRP treatment increased gene expression related to metabolism, cell survival, and communication between cells in cumulus cells. This suggests that PRP may help support egg development and fertility in women with poor ovarian response.
Researchers develop a potential new treatment for rare genetic diseases characterized by low levels of specific proteins. By adding an artificial poly(A) tail to mRNA, they boost protein production and aim to improve symptoms in people with protein-deficient disorders.
Researchers developed a new vaccine platform that provides robust, long-lasting protection against multiple flu strains and COVID-19. The vaccine boasts 100% survival rates in vaccinated mice following challenge with either virus.
Researchers from Yale University and Altos Labs have identified age-invariant genes that stay the same across all tissues during aging. These genes are linked to essential cellular functions, challenging the common belief that gene dysregulation drives aging.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
The Lung Cancer Research Foundation and Israel Cancer Research Fund are partnering to test an innovative new treatment for lung cancer. The project aims to explore the effects of a drug that targets IGF2BP1, a protein involved in cancer cell growth.
Researchers found a biomarker, RNA Polymerase II (RNAPII), associated with tumor aggressiveness and recurrence in meningioma and breast cancers. The study developed a novel profiling technology, Cleavage Under Targeted Accessible Chromatin (CUTAC), to measure gene transcription activity from DNA, which predicted cancer outcomes.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
A new genetic mutation, RUFY1-RET fusion, was discovered in a patient with stage IV CD-74-ROS1 fusion NSCLC who developed resistance to lorlatinib. The finding highlights the importance of ongoing genetic testing to guide therapy decisions.
Researchers at UCSF describe how to curb MYC levels by disrupting the protein assembly line controlled by RBM42. Disrupting RBM42 in pancreatic cancer cells stopped them from growing, suggesting drugs could be developed to do the same for other fast-growing cancers.
A study on six serodiscordant couples found that women who were immune to SARS-CoV-2 had elevated expression of the gene IFIT3 compared to their male partners. This suggests that overexpression of IFIT3 may offer protection against COVID-19 by inhibiting viral replication and preventing cell invasion.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
Researchers develop BEND lipids to improve LNP mRNA delivery and gene editing by breaking through the endosomal membrane. The new lipids outperform existing LNPs used in COVID-19 vaccines, with improved efficacy rates up to tenfold.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
Researchers developed a nanoparticle-based vaccine that generates antibodies targeting conserved regions of sarbecovirus receptor-binding proteins, offering broader protection against multiple strains. The vaccine demonstrated strong antibody responses and protection in animal studies against diverse SARS-CoV-2 and other sarbecoviruses.
Researchers designed metallo-supramolecular complexes that selectively bind to MPXV mRNA G4, modulating A5L protein expression and immune response activation. These findings highlight the significance of G4s in viral immunodominant protein expression and offer potential avenues for developing antiviral therapeutics.
Researchers developed a novel approach using lipid nanoparticles to deliver mRNA and siRNA, restoring tumor suppressors and inhibiting tumor drivers in prostate cancer cells. This technique holds promise for treating various types of cancer by targeting specific pathways related to tumor growth and suppression.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
A University of Cincinnati Cancer Center study identifies microRNA miR-205 as a promising new target to overcome breast cancer treatment resistance and improve outcomes. The research found that boosting levels of miR-205 could block the production of MED1, a protein responsible for treatment resistance, and improve treatment outcomes.
Researchers from Institute of Science Tokyo discovered that tristetraprolin (TTP) regulates inflammatory responses in basophils by promoting mRNA degradation. In TTP-deficient mice, aggravated allergic inflammation was observed, suggesting TTP as a key regulator of basophil-mediated immune responses.
Researchers have developed peptide-guided nanoparticles that can target specific cells in the brain, including neurons, marking a significant step toward potential mRNA treatments for neurological diseases. The innovation uses peptides to precisely deliver mRNA to endothelial cells lining blood vessels and neurons.
Researchers developed a new system, MEMPHIS, that models mRNA vaccine responses in a dish, providing insight into vaccine activity in vulnerable populations. The study found muted innate immune responses in people over age 60, indicating an impaired ability to support Th1 immunity.
Researchers at Chung-Ang University have identified a crucial role for specific tRNA fragments in cancer progression, revealing their ability to regulate gene expression and influence tumor growth. The study suggests that these fragments could serve as biomarkers for early-stage cancer detection and targets for therapeutic interventions.
Researchers developed an immunotherapeutic platform using lipid-based nanoparticles to deliver therapeutic mRNAs, showing improved efficacy and reduced toxicity. The therapy stimulates the immune system to recognize and eliminate cancer cells, while preserving beneficial immune responses.
A study by Indiana University School of Medicine researchers reveals that Toxoplasma gondii parasites use cap-independent translation to make proteins for dormant stages, evading drug treatment. This unconventional method has been found in both the parasite and human cells, making it a potential target for new treatments.
The study analyzed DNA from over 100,000 participants and found that nearly 2,000 carried at least one genetic variant linked to these diseases. The findings have led to life-changing discoveries and new insights into personalized medicine.
Researchers at Mass Eye and Ear developed an mRNA-based therapy to prevent scarring and blindness in PVR. The treatment, called RUNX1-Trap, targets a protein that regulates scar tissue formation, showing early promise for treating this eye disease.
Scientists at UChicago developed a new approach to study snoRNAs, uncovering thousands of previously unknown targets in human cells and mouse brain tissues. These discoveries suggest that snoRNAs may have a broader range of functions beyond guiding RNA modifications.
Zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), significantly reduced time-averaged lipoprotein(a) concentrations by over 80% during 36 weeks of treatment. This finding has potential implications for the treatment of atherosclerotic cardiovascular disease.